User profiles for V. W. Rebecca
vito rebeccaVerified email at wistar.org Cited by 14252 |
[HTML][HTML] Pre-clinical modeling of cutaneous melanoma
VW Rebecca, R Somasundaram, M Herlyn - Nature communications, 2020 - nature.com
Metastatic melanoma is challenging to manage. Although targeted- and immune therapies
have extended survival, most patients experience therapy resistance. The adaptability of …
have extended survival, most patients experience therapy resistance. The adaptability of …
Emerging strategies to effectively target autophagy in cancer
VW Rebecca, RK Amaravadi - Oncogene, 2016 - nature.com
Autophagy serves a dichotomous role in cancer and recent advances have helped delineate
the appropriate settings where inhibiting or promoting autophagy may confer therapeutic …
the appropriate settings where inhibiting or promoting autophagy may confer therapeutic …
A brief history of melanoma: from mummies to mutations
VW Rebecca, VK Sondak, KSM Smalley - Melanoma research, 2012 - journals.lww.com
In recent years, melanoma research has undergone a renaissance. What was once viewed,
at least in the metastatic setting, as an intractable and untreatable disease is now revealing …
at least in the metastatic setting, as an intractable and untreatable disease is now revealing …
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
KHT Paraiso, Y Xiang, VW Rebecca, EV Abel, YA Chen… - Cancer research, 2011 - AACR
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor
PLX4720. Immunohistochemical staining of a tissue array covering all stages of melanocytic …
PLX4720. Immunohistochemical staining of a tissue array covering all stages of melanocytic …
Stromal changes in the aged lung induce an emergence from melanoma dormancy
Disseminated cancer cells from primary tumours can seed in distal tissues, but may take several
years to form overt metastases, a phenomenon that is termed tumour dormancy. Despite …
years to form overt metastases, a phenomenon that is termed tumour dormancy. Despite …
[HTML][HTML] Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
…, X Zhou, A Gutierrez, VW Rebecca… - Nature …, 2021 - nature.com
Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight
into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse …
into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse …
PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer
VW Rebecca, MC Nicastri, C Fennelly, CI Chude… - Cancer discovery, 2019 - AACR
… VW Rebecca and MC Nicastri contributed equally to this article. … Writing, review, and/or
revision of the manuscript: VW Rebecca, MC Nicastri, C. Fennelly, JS Barber-Rotenberg, A. …
revision of the manuscript: VW Rebecca, MC Nicastri, C. Fennelly, JS Barber-Rotenberg, A. …
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms
KHT Paraiso, HE Haarberg, E Wood, VW Rebecca… - Clinical cancer …, 2012 - AACR
Purpose: The clinical use of BRAF inhibitors is being hampered by the acquisition of drug
resistance. This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six …
resistance. This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six …
[HTML][HTML] Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
…, J Wickramasinghe, AV Kossenkov, VW Rebecca… - Nature …, 2021 - nature.com
Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical
studies and therapeutic testing. It has been proposed that the mouse host affects tumor …
studies and therapeutic testing. It has been proposed that the mouse host affects tumor …
A unified approach to targeting the lysosome's degradative and growth signaling roles
VW Rebecca, MC Nicastri, N McLaughlin, C Fennelly… - Cancer discovery, 2017 - AACR
Lysosomes serve dual roles in cancer metabolism, executing catabolic programs (ie, autophagy
and macropinocytosis) while promoting mTORC1-dependent anabolism. Antimalarial …
and macropinocytosis) while promoting mTORC1-dependent anabolism. Antimalarial …